Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.55 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | METAP2 | P50579 | 4/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404436 | 0.79 | IDO1 (0.46) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL29428710 | 0.76 | NOS1 (0.50) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL18135157 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2DYRK1A | |
| SCHEMBL4133588 | 0.76 | NOS1 (0.50) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL7572936 | 0.76 | IDO1 (0.43) | NOS1AXLIDO1METAP2TDO2 | |
| SCHEMBL23464679 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL7918824 | 0.76 | IDO1 (0.43) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL5404343 | 0.76 | FGFR1 (0.44) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL20439372 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL12821601 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025236004-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4612128-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| CN-120129677-A | Compounds and their use for the treatment of heme lesions | 百时美施贵宝公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4524139-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-03-19 | — | — | EP | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-7919514-B2 | Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885AXL 2597/4885IDO1 1685/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | NOS1 1758/4885AXL 1439/4885IDO1 367/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | NOS1 2838/4885AXL 702/4885IDO1 2136/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885AXL 2597/4885IDO1 1685/4885 |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | NOS1 2512/4885AXL 4647/4885IDO1 3690/4885 |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | HBG1, HBG2, HBB | NOS1 2512/4885AXL 4647/4885IDO1 3690/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | NOS1 1255/4885AXL 3661/4885IDO1 2627/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885AXL 2597/4885IDO1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.